Project Grant R03CA299539
Award Date
7/3/25
Completion Date
6/30/27
Dollars Obligated
$153K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
This federal Project Grant award of $138,846 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop "lab-generated 'wild-like' mice" that mimic the adult human immune system. The goal is to create mouse models that better recapitulate human responses to cancer and immunotherapy, enabling more effective translation of findings from mouse studies to human treatments. The award was granted to the University Health...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013 to Sanford Research, a non-profit biomedical research organization, to develop the first genetically engineered mouse models that accurately replicate key features of human high-risk rhabdomyosarcoma. The goal is to use these advanced preclinical models to explore the role of the NOTCH1 signaling pathway as both a driver and potential therapeutic target for this aggressive form...
This Project Grant award for $399,187 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support Virginia Commonwealth University's research to develop novel genetically engineered mouse models to study the development of marginal zone lymphomas (MZL). The research aims to 1) investigate the impact of activation of the PI3K/AKT/mTOR pathway on MZL development, and 2) determine optimal drug combinations for targeting this pathway in MZL. This work seeks to establish...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $160,330 to the University of Illinois to develop novel lung adenocarcinoma models that better capture the initiation, progression, and composition of primary human lung tumors. The researchers aim to introduce oncogenic mutations into primary human lung stem and progenitor cells, and then culture them as tumor organoids or xenograft them into immunodeficient mice. This work seeks to...
This federal Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to develop the first genetically engineered mouse model of desmoplastic small round cell tumor (DSRCT) and define its pathobiology. The $527,904 award, which runs from September 1, 2024 to August 31, 2029, aims to: 1) establish a DSRCT mouse model by inducing the EWSR1-WT1 gene fusion and studying the effects of...
The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $158,365 to the University of North Carolina at Chapel Hill to study the effects of NRF2 signaling on the development of lung squamous cell carcinoma (LUSC). The research aims to understand how NRF2 activation impacts LUSC initiation, progression, and the tumor microenvironment using a novel genetically-engineered mouse model. The University of Washington will perform multi-omics...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
The National Cancer Institute (NCI) awarded a $585,931 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Pittsburgh. The grant, effective February 3, 2025 through January 31, 2030, will support a research project titled "Single-Cell Congruence Evaluation and Selection of Cancer Models Towards Precision Medicine." The project aims to: 1) Identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer,...